1. HOME
  2. IR Information
  3. Qol HD At-A-Glance
  4. Further growth in the field of "medicine and healthcare"

Further growth in the field of "medicine and healthcare"

Aiming to become a comprehensive healthcare company providing seamless medical care services

The Qol Group aims to achieve further growth by strengthening new businesses and maximizing group synergy, as a comprehensive healthcare company that seamlessly provides a full lineup of services to patients in the healthcare field, spanning research and development, manufacturing, sales and dispensing.

Integrated Healthcare Company Concept: From R&D to manufacturing, sales, and dispensing to patients. R&D: Fujinaga Pharmaceutical Co., Ltd., APO PLUS STATION (CRO Business). Manufacturing: Manufacturing Factory, Fujinaga Pharmaceutical Co., Ltd., DAIICHI SANKYO ESPHA CO., LTD. Sales: As MR, Fujinaga Pharmaeutical Co., Ltd, DAIICHI SANKYO ESPHA CO., LTD., APO PLUS STATION (CSO Business), Medical Qol (Sales Support). As a dispensing pharmacy, Nationwide stores by Qol, APO PLUS Career (Medical Professional Referral Dispatch Business), Medical Qol (Sales Tools). For patients: Qol.

Expansion of business scale to contribute to healthcare; improvement of quality in the Pharmacy business; expansion of scale in the Medical-related business; and further growth through by DAIICHI SANKYO ESPHA

Consolidated Performance Targets: FY2026 net sales of ¥300 billion, operating profit of ¥24 billion. Unit price is \10 Million, FY2021 Operating profit 98 Net sales 1,661 FY2022 Operating profit 94 Net sales 1,700 FY2023 Operating profit 83 Net sales 1,800 FY2024 target Operating profit 150 Net sales 2,700 FY2025 target Operating profit 186 Net sales 2,862 FY2026 target Operating profit 240 Net sales 3,072

Shareholder Returns

Stable return of profits and enhancement of shareholder benefit program

The Qol Group's basic policy is to pay stable and continuous dividends to shareholders while giving due consideration to ensuring growth funds for future business development and reinforcement of its management base.
We are also enhancing our shareholder benefit program with the aim of increasing the number of long-term shareholders.

Trends in Dividend per Share and Dividend Payout Ratio. The left-hand side of the vertical axis indicates dividend per share (unit: yen), and the right-hand side indicates dividend payout ratio (unit: percentage). The horizontal axis indicates forecasts from the fiscal years endind March31, 2017 to the fiscal years ending March 31, 2025. Year ended March 31, 2017 Dividend per share 24.00 Dividend payout ratio 18.7% Year ended March 31, 2018 Dividend per share 28.00 Dividend payout ratio 19.8% Year ended March 31, 2019 Dividend per share 28.00 Dividend payout ratio 27.5% Year ended March 31, 2021 Dividend per share 28.00 Dividend payout ratio 31.3% Year ended March 31, 2022 Dividend per share 28.00 Dividend payout ratio 18.7% Year ended March 31, 2023 Dividend per share 32.00 Dividend payout ratio 20.9% Year ended March 31, 2024 Dividend per share 30.00 Dividend payout ratio 22.9% Year ending March 31, 2025 (forecast) Dividend per share 34.00 Dividend payout ratio 22.2%, including increase of 4.00